Naltrexone: disposition, metabolism, and effects after acute and chronic dosing
- PMID: 954353
- DOI: 10.1002/cpt1976203315
Naltrexone: disposition, metabolism, and effects after acute and chronic dosing
Abstract
The disposition of naltrexone during acute and chronic administration of 100-mg oral dose was studied in 4 subjects. Following an acute dose the mean (X) peak naltrexone plasma level was 43.6 +/- 29.9 ng/ml at 1 hr and for the major biotransformation product, beta-naltrexol, was 87.2 +/- 25.0 ng/ml at 2 hr. Twenty-four hours after the dose the X levels of naltrexone and beta-naltrexol declined to 2.1 +/- 0.47 and 17.6 +/- 5.0 ng/ml, respectively. Following chronic administration and X peak plasma levels of naltrexone and beta-naltrexol rose to 46.4 +/- 18.5 and 158.4 +/- 89.9 ng/ml at 1 hr, but by 24 hr both compounds declined to levels of the same order as in the acute state at 24 hr. Plasma levels of naltrexone and beta-naltrexol measured 24 hr after the daily doses of naltrexone throughout the study indicated that steady-state equilibrium was rapidly attained and that there was no accumulation of naltrexone and beta naltrexol in the plasma after chronic treatment on 100 mg oral doses. Biexponential kinetics were observed for naltrexone and beta-naltrexol in the first 24 hr. The half-life of naltrexone and beta-naltrexol decreased slightly from the acute to thechronic study from 10.3 +/- 3.3 to 9.7 +/- 1.1 hr and from 12.7 +/- 2.6 to 11.4 +/- 2.0 hr. The plasma levels of naltrexone declined slowly from 24 through 72 hr from 2.4 to 1.7 ng/ml, with an apparent half-life of 96 hr. The renal clearance data indicate that naltrexone is partially reabsorbed while beta naltrexol is actively secreted by the kidney. During acute and chronic naltrexone administration the mean fecal excretion was 2.1% and 3.6% while urinary excretion was 38% and 70% of the dose in a 24-hr period. Opiate antagonism to 25 mg heroin challenges was nearly complete through 48 hr after naltrexone. At 72 hr the objective responses reappeared to a greater extent than the subjective ones. Correlation coefficient (r) between naltrexone plasma levels and opiate antagonism was 0.91 and between individual half-life of naltrexone and opiate antagonism it was 0.99.
Similar articles
-
Metabolism and disposition of naltrexone in man after oral and intravenous administration.Drug Metab Dispos. 1981 Jul-Aug;9(4):369-75. Drug Metab Dispos. 1981. PMID: 6114837
-
The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics.NIDA Res Monogr. 1981;28:147-58. NIDA Res Monogr. 1981. PMID: 6791001
-
The urinary excretion profiles of naltrexone in man, monkey, rabbit, and rat.Drug Metab Dispos. 1976 Sep-Oct;4(5):474-8. Drug Metab Dispos. 1976. PMID: 10147
-
Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.J Clin Psychiatry. 1984 Sep;45(9 Pt 2):15-9. J Clin Psychiatry. 1984. PMID: 6469932
-
Review of naltrexone, a long-acting opiate antagonist.Clin Pharm. 1984 May-Jun;3(3):273-80. Clin Pharm. 1984. PMID: 6329589 Review.
Cited by
-
Stimulus effects of delta(9)-THC and its interaction with naltrexone and catecholamine blockers in rats.Psychopharmacology (Berl). 1977 Oct 20;54(2):193-5. doi: 10.1007/BF00426779. Psychopharmacology (Berl). 1977. PMID: 200967
-
Development of vaccines to treat opioid use disorders and reduce incidence of overdose.Neuropharmacology. 2019 Nov 1;158:107662. doi: 10.1016/j.neuropharm.2019.06.001. Epub 2019 Jun 4. Neuropharmacology. 2019. PMID: 31173759 Free PMC article. Review.
-
Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.Br J Clin Pharmacol. 2000 Nov;50(5):465-71. doi: 10.1046/j.1365-2125.2000.00281.x. Br J Clin Pharmacol. 2000. PMID: 11069441 Free PMC article.
-
Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade.Neuropsychopharmacology. 2023 Jan;48(2):299-307. doi: 10.1038/s41386-022-01416-z. Epub 2022 Aug 17. Neuropsychopharmacology. 2023. PMID: 35978096 Free PMC article.
-
Pharmacologic treatments for opioid dependence: detoxification and maintenance options.Dialogues Clin Neurosci. 2007;9(4):455-70. doi: 10.31887/DCNS.2007.9.2/hkleber. Dialogues Clin Neurosci. 2007. PMID: 18286804 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources